DB BIOTECH

DB Biotech Inc., Kosice, Slovakia, EU is focused on the design and production of high quality rabbit clonal antibodies developed by a novel and proprietary in-vitro cloning technology which has been developed and perfected by the DBB scientific team over a period of 20 years. DB Biotech monospecific clonal antibodies are uniquely characterized by exceptional specificity, affinity and avidity. The DB Biotech in-vitro cloning technology enables the preparation of a pure immunoglobulin fraction corresponding to a single clone of B lymphocytes. The obtained immunoglobulin recognizes only one single linear epitope on the antigen molecule, making a DB Biotech antibody comparable in quality to its monoclonal analogue. In addition, the influence of the protein tertiary structure – frequently present in epitopes formed during production of monoclonal antibodies – is eliminated in the immunoglobulins corresponding to the clonal antibody. DB Biotech produced antibodies correspond strictly to the conserved linear epitope of the antigen molecule, yielding a higher-quality, more specific antibody with significantly better affinity and avidity. Founded in 2006 for business please contact Sales sales@dbbiotech.com or dbbiotech@dbbiotech.com